Biotech Growth’s net asset value per share increased 20.5% during the six month period ended 30 September. The Company’s benchmark, the Sterling-adjusted NASDAQ Biotechnology Index, increased 23.2% during the same period. The Company’s share price increased 21.7% during the period. Currency movement contributed significantly to performance, as the Dollar appreciated 10% relative to the Pound […]
Over the year to 31 March 2016, Biotech Growth Trust’s net asset value per share fell by 24.8% during the year, underperforming the Company’s benchmark, the NASDAQ Biotechnology Index, measured in sterling terms, which fell by 21.8%. The Company’s share price fell further, by 26.3%, as the discount of the Company’s share price to the […]
Biotech shares were weak in the six months that ended 30 September 2015. Biotech Growth Trust reports that its NAV fell by 18.6% over this period, 5% more than the 13.6% fall in the NASDAQ Biotechnology Index. The company’s shares fell by 19.3%. The Chairman said the fall in the value of many biotechnology companies […]
BIOG : Another great period for Biotech Growth Trust Biotech Growth Trust beat its benchmark over the six months that ended on 30 September 2014 delivering a return on net assets of 20.3% vs. a return on the NASDAQ Biotechnology Index of 19.1%. The share price return was 21.4%. Top contributors to performance in the […]
Biotech Growth seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted). In order to achieve its investment objective, Biotech Growth invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The website can be found here.
BlackRock Throgmorton Trust Investment companies | Update | 22 November 2023 Growth in all things BlackRock Throgmorton Trust (THRG) remains committed to the UK quality-growth small-and-mid-caps that has long characterised the trust. While the UK small-and-mid-cap sector has appeared to have been out of favour recently, THRG’s holdings seem to have stock specific strengths that […]
BlackRock Throgmorton Trust Investment companies | Update | 22 November 2023 Growth in all things BlackRock Throgmorton Trust (THRG) continues to demonstrate its commitment to UK quality-growth small-and-mid-caps that has long characterised the trust, even in the face of apparent headwinds, such as rising interest rates and lower UK economic growth. While the UK small-and-mid-cap […]
BlackRock Throgmorton Trust Investment companies | Update | 22 November 2023 Growth in all things BlackRock Throgmorton Trust’s (THRG’s) continues to demonstrate its commitment to UK quality-growth small-and-mid-caps that has long characterised the trust, even in the face of apparent headwinds. While the UK small-and-mid-cap sector has been somewhat out of favour recently, the stock-specific […]
Investment trust insider on RTW Biotech – James Carthew: RTW Biotech will succeed with or without Arix I was singing the praises of capital markets days last week. Last Tuesday, I managed to get along to one held by RTW Biotech Opportunities (RTW). The day was planned some time ago, but the timing was great […]
Baillie Gifford European Growth (BGEU) has published its annual results for the year ended 30 September 2023, during which it provided NAV and share price total returns of 8.3% and 8.6% respectively, but these were significantly behind its benchmark, the FTSE Europe ex UK Index, which it says returned 20.5% (all figures in sterling terms). […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated